admin – Page 33 – Swanson Reed | Specialist R&D Tax Advisors

CenExel Clinical Research Announces the Acquisition of iResearch

CenExel Clinical Research has announced their acquisition of iResearch, a leading multi-specialty research site business. iResearch is known for their expertise in and experience in conducting clinical studies including Phase I-IV. This experience includes more than 200 clinical trials in both inpatient and outpatient settings.

This acquisition is poised to strengthen CenExel’s leading central nervous system (CNS) trial capabilities in both psychiatry and neurology therapeutic areas.

Now called CenExel iResearch, the company operates in a state-of-the-art clinical research facility with a 10,000 sq ft inpatient unit. CenExel iResearch is led by co-founders Heather Beitz and Sara Castle, who serve as CEO and COO, respectively. Dr. Kimball Johnson serves as the organization’s Medical Director, with 30+ years of experience, as part of the CenExel iResearch team of 10 principal investigators. Zach Mitchell serves as the organization’s Director of Business Development, leading both sales and strategic operations, and will serve in a similar capacity with CenExel iResearch moving forward.

CenExel iResearch will benefit from CenExel’s extensive network which offers fully integrated and collaborative processes from centralized budgeting, business development, quality management and more.

CenExel was formed in 2018, and since its formation, has strategically invested to support organic growth in its centers of excellence, while also pursuing acquisitions of state-of-the-art research centers across the U.S. The mission of CenExel is to work with trial Sponsors and Contract Research Organizations to drive efficiencies in clinical research, while reducing the costs and development timelines for innovative therapies to advance patient care.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

CenExel Clinical Research Announces the Acquisition of iResearch

CenExel Clinical Research has announced their acquisition of iResearch, a leading multi-specialty research site business. iResearch is known for their expertise in and experience in conducting clinical studies including Phase I-IV. This experience includes more than 200 clinical trials in both inpatient and outpatient settings.

This acquisition is poised to strengthen CenExel’s leading central nervous system (CNS) trial capabilities in both psychiatry and neurology therapeutic areas.

Now called CenExel iResearch, the company operates in a state-of-the-art clinical research facility with a 10,000 sq ft inpatient unit. CenExel iResearch is led by co-founders Heather Beitz and Sara Castle, who serve as CEO and COO, respectively. Dr. Kimball Johnson serves as the organization’s Medical Director, with 30+ years of experience, as part of the CenExel iResearch team of 10 principal investigators. Zach Mitchell serves as the organization’s Director of Business Development, leading both sales and strategic operations, and will serve in a similar capacity with CenExel iResearch moving forward.

CenExel iResearch will benefit from CenExel’s extensive network which offers fully integrated and collaborative processes from centralized budgeting, business development, quality management and more.

CenExel was formed in 2018, and since its formation, has strategically invested to support organic growth in its centers of excellence, while also pursuing acquisitions of state-of-the-art research centers across the U.S. The mission of CenExel is to work with trial Sponsors and Contract Research Organizations to drive efficiencies in clinical research, while reducing the costs and development timelines for innovative therapies to advance patient care.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Annovis Bio and NIA Enter into Cooperative Research and Development Agreement

Annovis Bio, Inc. has announced a Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging (NIA), a subsect of the National Institutes of Health. This CRADA will support a collaboration between NIA and Annovis as they develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived extracellular vesicles (EV) containing potential biomarkers of neuronal function and viability.

Annovis Bio is a clinical-stage drug platform tackling neurodegenerative diseases including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Buntanetap is their lead candidate and simultaneously inhibits the production of multiple neurotoxic brain proteins including amyloid precursor protein (APP), Tau and α-Synuclein. These proteins have been seen to impair axonal transport leading to cell death.

Annovis Bio’s buntanetap sets itself apart from other AD drugs in development by inhibiting the proteins before they can even form. These other drugs in development typically attempt to remove an already formed protein.

The collaboration aims to validate the pharmacodynamic biomarkers by comparing the abundance of the biomarker in EVs isolated from blood and cerebrospinal fluid with the change in biomarker levels after a buntanetap dose. Biomarkers will be assessed in de-identified plasma and CSF samples of Alzheimer’s Disease (AD), Parkinson’s disease (PD), and control participants from Annovis’ Phase 2a clinical trials.

Neurodegenerative diseases are a truly unmet medical need. Annovis Bio’s novel approach to addressing neurodegeneration offers a new method with potential to reverse the toxic cascade caused by neurotoxic proteins. By preventing impaired axonal transport, nerve cell death can be prevented before it is even begun.

Are you developing new clinical pharmaceuticals? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Oklahoma Senate Passes Bill to Support R&D and Innovation in the State

The Oklahoma Senate has passed a bill by Senator Chris Kidd, R-Waurika, to attract research and development companies to Oklahoma. The bill will return to the House for final consideration before moving on to the governor’s desk.

House Bill 4354 – referred to as the Oklahoma Research and Development Act – was drafted to direct the Oklahoma Center for the Advancement of Science and Technology (OCAST) to provide matching grants for eligible companies. Eligible companies then partner in projects with research universities or nonprofit research institutions in the state with the intention of fostering development of key industries.

Sen. Kidd has been working to diversify the Oklahoman economy, sponsoring research activities, and increasing the state’s competitiveness.

“Currently, OCAST’s highly competitive awards only go to existing companies already in our state. This bill would set aside a pool of funds specifically for companies who choose to relocate here and want to perform research and development with our great research institutions.” Kidd said.

Under the Research and Development Attraction Grants Program, the matching grants could be awarded to cover up to 50 percent of the cost of the project, not to exceed $100,000. To be eligible, a business must:

Be an Oklahoma-based small business (less than 100 employees);
Operate in aerospace and autonomous systems, life sciences, or energy diversification;
Partner with an Oklahoma-based research entity;
Conduct its research and development project within Oklahoma; and
File an application with OCAST showing the total cost of the project and demonstrating private capital to fund at least 50 percent of the project.

Are you developing new technology for a new or existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

First Solar has Finalized Multi-Year Supply Agreement with Leeward Renewable Energy

First Solar has announced a multi-year framework supply agreement with Leeward Renewable Energy (LRE). In this agreement, First Solar will provide LRE with 1 GWdc of its ultra-low carbon thin-film photovoltaic (PV) solar modules. LRE will deploy these modules across its 20 GW solar development and construction pipeline in the U.S. over 2023 and 2024.

First Solar has been innovating the PV and solar cell industry for decades, achieving incredible energy yields, lower LCOE, and stable grid integrations. With R&D centers in Ohio and California, First Solar’s thin film PV modules have a carbon footprint that is 2.5 times lower and a water footprint that is three times lower than the average crystalline silicon solar panel made with cells produced in China.

“Sophisticated project developers such as LRE are looking to secure their development portfolios by partnering with a module supply partner that offers a reliable, clean energy solution with a long-term agreement structure,” said Georges Antoun, chief commercial officer at First Solar.

The company intends to invest $680 million to expand America’s domestic PV solar manufacturing capacity by 3.3 GW annually. The first step to this is the opening of its third US manufacturing facility in Lake Township, Ohio. The new facility is expected to be commissioned in the first half of 2023 and when fully operational will scale the company’s Northwest Ohio footprint to a total annual capacity of 6 GW, which is believed to make it the largest fully vertically integrated solar manufacturing complex outside of China.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Viance Brings on Dr. Rufai Ibrahim to Expand their R&D Team

Viance, LLC has announced the expansion of their R&D department. They have brought on Dr. Rufai Ibrahim, an expert in Polymer Chemistry. Dr. Ibrahim has extensive experience in formulation chemistry in the biotechnology and coatings industry.

North Carolina-based Viance develops and manufactures an extensive range of advanced wood treatment technologies and services to the global wood preservation industry. They’ve been leading innovation in this industry for over 30 years with the design and development of a wide range of advanced building material solutions. Their products aim to improve performance and durability regardless of application.

Between the expertise of Dr. Ibrahim and Dr. Kevin Archer, Director of Research and Development with Viance, the company will expand their efforts to develop new chemistries for wood preservatives and fire retardant product formulations.

“Our continuing goal is to provide the wood preservation industry with environmentally advanced solutions for residential, commercial, industrial, and agricultural applications.” said Dr. Archer.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Accern Announces $20M Raised in Series B Funding

Accern Corp. has announced a successful Series B funding round resulting in $20 million. This capital will be directed towards “product-led growth” and specifically R&D efforts for their AI technologies.

Accern is focused on accelerating AI workflows for financial service enterprises using a no-code AI platform. They’ve conducted extensive R&D to create adaptive Natural Language Processing (NLP) and forecasting features to meet the needs in a wide range of AI use cases. While they started out by curating a narrow set of financial information pertaining to stocks, they then broadened their scope to other areas including credit and fraud monitoring.

“Accern’s enterprise focus is to accelerate innovation by providing organizations with … models that enable them to more efficiently transform their unstructured data into real business intelligence — while cutting down on time and costs,” Kumesh Aroomoogan, Cofounder of Accern, said. “Many of our customers use us to enhance their existing models, business intelligence dashboards and products with new features from text data in a no-code workflow.”

The no-code aspect of the product means any business can begin gathering data and gaining insights into their business. The system takes care of it for you , so no data science background is needed. It further cuts down the time needed to gain those insights, turning mass amounts of unstructured textual data (eg. news, social media, financial filings) into insights without the need for any code at all.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Thyreos has Received an SBIR Grant for their Vaccine Research

Sartorius AG to Open Center of Excellence in Michigan

Thyreos, a Nebraska based vaccine research company, has been awarded a Small Business Innovation Research (SBIR) grant from the US Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA). The grant is intended to support the development of a new vaccine to protect against Infectious Bovine Rhinotracheitis (IBR), a disease that causes respiratory illness in cattle.

Thyreos’ vaccines use proprietary technology capable of protecting the animals nervous system by removing the viral component responsible for the viral transmission. Bovine alphaherpesvirus 1 (BoHV-1) is endemic in the US cattle population leading to a significant loss of milk and viable beef.

Thyreos R2 technology can selectively remove the neuroinvasive potential of the herpesvirus by removing a key viral component. The SBIR program will support the continued research and innovation to bring this technology to scale.

“We are pleased to receive a Phase I SBIR grant from the USDA National Institute of Food and Agriculture,” said Eric Zeece, CEO of Thyreos. “BoHV-1 and associated respiratory diseases are responsible for significant costs to cattle producers. Thyreos R2 vaccines represent a new technological approach to developing alpha herpesvirus vaccines that decrease producer costs through improved efficacy and safety.”

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Vitti Labs Announces FDA Approval for Phase II IND Clinical Trial

Vitti Labs LLC, a research and development tissue bank, has announced FDA approval of their Phase II investigational new drug (IND) clinical trial. With this approval, they can move forward with a Phase II Outpatient Clinical Trial using a combination of Umbilical Cord Mesenchymal Stem Cells and Mesenchymal Stem Cell Exosomes to treat Pulmonary Fibrosis secondary to COVID-19.

COVID-19 commonly results in the presence of one of two respiratory manifestations. The first manifestation is a significant reduction in the diffusing capacity of the lungs (FLCO). The second is associated pulmonary interstitial damage. Even a full year after a recovery from COVID-19, the incidence rate of impaired DLCO and persistent lung damage is still over 30%. These persistent complications have caused substantial population morbidity, long-term disability, and even death due to the fibrotic lung progression.

With this study, Vitti Labs believes they will be able to move forward with much needed treatment modalities for these and other respiratory and pulmonary diseases. Vitti Labs is the first to bring a Phase II trial for this treatment using these therapeutics.

The company harvests biomaterials from the umbilical cord and placenta, using their properties to activate and support the repair of the body. They harvest through the bio-ethically donation of birth tissue from healthy and consenting mothers across the United States.

Are you developing new pharmaceuticals for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Scorpion Biological Services Announces New Kansas Biomanufacturing Facility

Global Microbiology Industry Projected to Grow Due to R&D Expenditure and Innovation

Scorpion Biological Services, a contract development and manufacturing organization (CDMO) focused on cell- and gene-based therapies, has announced their plan to build a $60 million biodefense-focused plant in Kansas. This plan includes the use of a planned development partnership with a private developer, the state of Kansas, and university affiliates.

The new plant will be 500, 000 sq ft and intended to service around 144, 000 L of biomanufacturing capacity across 48 bioreactors for the production of large molecule biologics.

One specific goal of the Kansas plant will be to support scale production of Anthim (obiltoxaximab), an antitoxin against anthrax, which could be used in defense against a potential anthrax attack when alternative therapies are not available or are not appropriate.

The firm intends to use a US-based supply chain and to develop trains focused on products for the Strategic National Stockpile (SNS). Scorpion says this is partly because 70% of the drug products in the SNS will be gone over the next four years.

Scorpion anticipates that the facility will be complete, fully operational and staffed by April 2027. Once complete, the firm anticipates employing over 500 individuals, largely from the local talent pool.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.